MedTrace Logo

A Study of Amorphous Calcium Carbonate in Postmenopausal Women

NCT06728462 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 205

Last updated 2025-03-07

No results posted yet for this study

Summary

Using the FREEDOM substudy as a benchmark, evaluate the effects of amorphous calcium carbonate (ACC) on bone mineral density (BMD) in postmenopausal women, both with and without the combination of Denosumab treatment.

Conditions

  • Calcium
  • Osteoporosis
  • Bone Mineral Density
  • Bone Turnover Marker
  • Denosumab

Interventions

DIETARY_SUPPLEMENT

Amorphous calcium carbonate

The usual dose for oral use is 5 ACC tablets (equal to 1000 mg calcium element) daily given after meals.

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • Universal Integrated Corp.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-04
Primary Completion
2025-12-14
Completion
2027-03-01

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06728462 on ClinicalTrials.gov